Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a leader in autoimmune diagnostics, providing specialized testing solutions through its CLIA-certified laboratory and proprietary AVISE® platform. This page serves as the definitive source for verified news and announcements related to the company’s advancements in rheumatology diagnostics, financial developments, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study outcomes, and operational achievements. Our curated collection includes earnings reports, partnership announcements, and insights into biomarker research that drives Exagen’s industry-leading tests for conditions like lupus and rheumatoid arthritis.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and medical accuracy. Bookmark this page to efficiently track Exagen’s progress in improving diagnostic clarity for autoimmune diseases while staying informed about its role in advancing personalized medicine.
Exagen Inc. (Nasdaq: XGN) reported preliminary financial results for Q4 2020, projecting testing revenue between $10.5 million and $10.8 million, reflecting an 11% to 15% increase from Q3 2020. The company delivered approximately 28,600 AVISE CTD tests, backed by a record 635 healthcare provider adopters and a 99% retention rate. Despite COVID-19 challenges, Exagen's core testing business showed strong performance, positioning it for growth in 2021. Full financial results, including SIMPONI revenue, will be released in March 2021.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN) is set to participate in the 2021 ICR Conference from January 11-14, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will hold a virtual fireside chat on January 14 at 11:30 AM ET. Attendees can schedule one-on-one meetings with management during the event. Exagen focuses on transforming care for patients with autoimmune diseases through innovative testing products, aiming to enable timely diagnosis and therapeutic intervention.
Exagen Inc. (Nasdaq: XGN) has announced that all AVISE test offerings are now contracted as in-network services with St. Charles Health System, the largest healthcare provider in Central Oregon. This partnership is expected to enhance patient care by making AVISE testing accessible to rheumatologists for the diagnosis and monitoring of autoimmune diseases, especially systemic lupus erythematosus (SLE). CEO Ron Rocca highlighted the significance of this arrangement for improving community health outcomes.
Exagen Inc. (Nasdaq: XGN) announced its participation in key December investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will feature a recorded company presentation available from November 23 to December 3, 2020. Additionally, Ron Rocca, the President and CEO, will engage in a Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 10:30 am EST. Exagen focuses on advancing care for patients with autoimmune diseases, utilizing its innovative AVISE® testing products.
Exagen Inc. (Nasdaq: XGN) has extended its collaboration agreement with GlaxoSmithKline (GSK) to improve the diagnosis of systemic lupus erythematosus (SLE), a major autoimmune disease. This partnership aims to enhance awareness of the importance of early diagnosis, which currently takes an average of nearly six years. The agreement will continue to utilize Exagen's proprietary AVISE® laboratory tests to support SLE patients in achieving better health outcomes. The details of the agreement remain confidential, following a similar extension made last year.
Exagen Inc. (Nasdaq: XGN) reported strong Q3 2020 results with revenue of $10.8 million, reflecting a 20% increase from Q2 2020 and a 3% rise year-over-year. Despite COVID-19 challenges, the company delivered 26,201 AVISE® tests and achieved a 99% retention rate among healthcare providers. Significant additions of 14 million covered lives were made, enhancing testing access. Although net loss increased to $4.3 million, gross margin improved to 60%. Exagen continues to strengthen its market position through innovative products and strategic partnerships.
Exagen Inc. (Nasdaq: XGN) announced management participation in November investor conferences to enhance its presence in the healthcare sector. They will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:00 pm EST and engage in a Fireside Chat at the Canaccord Genuity MedTech & Diagnostics Forum on November 19, 2020, at 11:30 am EST. Exagen focuses on innovative testing for autoimmune diseases and aims to improve care through its AVISE® brand products.
Exagen Inc. (Nasdaq: XGN) has partnered with Brigham and Women’s Hospital to study the incidence and risk factors of rheumatic autoimmune diseases in COVID-19 survivors. The year-long study will involve positive PCR-confirmed COVID-19 patients categorized by disease severity. Participants will complete questionnaires and undergo testing with AVISE® biomarkers to assess new rheumatic disease symptoms and autoantibody formation. This research aims to clarify the association between COVID-19 recovery and autoimmune disease development, addressing current knowledge gaps in this area.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the quarter ending September 30, 2020, on November 10, 2020, after market close. The conference call, led by CEO Ron Rocca and CFO Kamal Adawi, will begin at 4:30 PM ET. Investors can join the call by dialing (877) 407-3982 or via webcast on the Exagen investor relations website. A replay will be accessible until November 17, 2020. Exagen focuses on enhancing care for patients with autoimmune diseases through innovative testing products under its AVISE® brand.
Exagen Inc. (XGN) announced participation in the ACR Convergence 2020, a virtual meeting scheduled from November 5-9, where its research on autoimmune diseases, specifically lupus, will be presented. Chief Scientific Officer Anja Kammesheidt emphasized their commitment to advancing understanding of cell-bound complement activation products (CB-CAPs). Several abstracts have been accepted for presentation, showcasing innovative testing products under the AVISE® brand. This event is anticipated to enhance awareness and adoption of Exagen's diagnostics.
